Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206381 | 0.85 | NPSR1 (0.54) | PREPNPSR1GFERCTRB1ALDH1A1 | |
| SCHEMBL26364677 | 0.82 | PREP (0.59) | PREPNPSR1GFERCTRB1ALDH1A1 | |
| SCHEMBL4387236 | 0.80 | PREP (0.54) | PREPNPSR1GFERCTRB1ALDH1A1 | |
| SCHEMBL4392300 | 0.80 | NPSR1 (0.69) | PREPNPSR1GFERCTRB1ALDH1A1 | |
| SCHEMBL4388868 | 0.80 | NPSR1 (0.69) | PREPNPSR1GFERCTRB1ALDH1A1 | |
| SCHEMBL10756725 | 0.79 | PREP (0.62) | PREPNPSR1GFERCTRB1ALDH1A1 | |
| SCHEMBL489615 | 0.79 | PREP (0.62) | PREPNPSR1GFERCTRB1ALDH1A1 | |
| SCHEMBL10756717 | 0.79 | PREP (0.62) | PREPNPSR1GFERCTRB1ALDH1A1 | |
| SCHEMBL4386402 | 0.79 | GFER (0.58) | PREPNPSR1GFERCTRB1ALDH1A1 | |
| SCHEMBL5755965 | 0.78 | PREP (0.54) | PREPNPSR1GFERCTRB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193411-A1 | Anti-viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | PREP 113/4885NPSR1 1912/4885GFER 4411/4885 |
| US-20100055071-A1 | Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | PREP 113/4885NPSR1 1912/4885GFER 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.